Gastrointestinal Cancer News & Features
Women with poor metabolic health have a greater risk of colorectal cancer than those with increased weight.
Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.
An investigation into whether onset or worsening of diabetes causes pancreatic cancer or vice versa was presented at the 2017 European Cancer Congress.
Research presented at the 2017 European Cancer Congress describes the potential of a noninvasive diagnostic test for esophageal and gastric cancers that measures chemicals in the breath.
Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
Gastrointestinal Cancer Clinical Trials
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|